维昇药业致力于内分泌相关疾病治疗，将全球领先的治疗方法及药品引入中国，希望能够让更多的中国患者快速地接触到全球先进可靠的治疗方案。
Investors 3
Mentions in press and media 5
| Date | Title | Description |
| 14.08.2024 | A New Dawn for Hypoparathyroidism: VISEN Pharmaceuticals' Breakthrough in Treatment | In the world of medicine, breakthroughs often emerge from the shadows of despair. For patients suffering from chronic hypoparathyroidism, a condition marked by insufficient parathyroid hormone (PTH), hope has arrived. VISEN Pharmaceuticals ... |
| 12.08.2024 | VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide achieved primary and key secondary endpoints in the treatment of adults with hypoparathyroidism | 77.6% of patients treated with palopegteriparatide in the PaTHway China Trial achieved the primary multi-component endpoint compared to 0.0% for placebo (p |
| 12.08.2024 | VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide achieved primary and key secondary endpoints in the treatment of adults with hypoparathyroidism | 77.6% of patients treated with palopegteriparatide in the PaTHway China Trial achieved the primary multi-component endpoint compared to 0.0% for placebo (p |
| 08.03.2024 | VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China | SHANGHAI, March 8, 2024 /PRNewswire/ -- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, today announced that the Biologics License Application (BLA) for Lonapegsomatropin (TransCon hGH) ... |
| 16.11.2023 | Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial | SHANGHAI, Nov. 16, 2023 /PRNewswire/ -- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, is pleased to announce the topline results from the ACcomplisH China Phase 2 Trial in children wit... |
Reviews 0
